HASBROUCK HEIGHTS, N.J., Aug. 14, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the second quarter of 2012. Nymox reported a net loss of $1,721,128, or $0.05 per share, for the quarter and $3,568,103, or $0.11 per share, for the six months ended June 30, 2012, compared to $1,948,132, or $0.06 per share, for the quarter and $6,379,223, or $0.20 per share, for the six months ended June 30, 2011. Net losses include stock-based compensation charges of $129,666 for the six months ended June 30, 2012 and $3,666,158 in the comparative period in 2011. The decrease in net losses is attributable primarily to lower stock-based compensation charges in 2012 compared to 2011.

Revenues from sales amounted to $209,673 for the six months ended June 30, 2012, compared to $222,697 for the same period in 2011. Additionally, for the six months ended June 30, 2012 and 2011, amounts of $1,308,800 respectively were recognized as revenue relating to the upfront payment received from Recordati in December 2010. The weighted average number of common shares at June 30, 2012 was 33,025,559, compared to 32,597,725 at June 30, 2011.

Paul Averback, CEO of Nymox said, "During the second quarter Nymox made steady progress in the development of NX-1207 for BPH and low-risk localized prostate cancer. The pivotal Phase 3 trials of NX-1207 for BPH are expected to reach full enrollment in the near term and the Safety Committee reviews of ongoing safety data continue to be positive. The U.S. Phase 3 re-injection trial of NX-1207 for BPH completed enrollment in July in only 12 months. The enthusiastic response from patients who had previously received an intraprostatic injection in an earlier trial and enrolled for a second injection indicates that patients are comfortable with the convenience and relative painlessness of the procedure. The Phase 2 prostate cancer study has already enrolled its first patients and patient accrual is progressing well. The Company expects to report further trial results later this year."

"NX-1207 was featured in a well-received Symposium and Panel Discussion at the Annual Meeting of the American Urological Association in Atlanta in May. Urologists have been very enthusiastic about the potential of NX-1207 for the treatment of BPH, and for focal treatment of low grade cancer of the prostate," Dr. Averback added.

Nymox Pharmaceutical Corporation is engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. The Company's new drug for benign prostatic hyperplasia (BPH) is in Phase 3 development in the U.S. and Europe. The Company's candidate drug for prostate cancer is currently in Phase 2 testing in the U.S. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: Roy Wolvin         Nymox Pharmaceutical Corporation         1-800-93NYMOX         www.nymox.com